Tandem Diabetes Care (TNDM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$19.11-3.87%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Tandem Diabetes Care is growing revenue about 5% year over year. Gross margin improved to 55% and is guided to 56.5% for 2026. Cash from operations turned positive to $11.1 million in Q1 2026. The company is expanding internationally and increasing pump shipments as planned.
The company remains unprofitable with negative EPS guidance for 2026. Recent share price fell 27% from highs, reflecting market doubts. Operating risks include management changes and ongoing losses. Revenue growth and margin gains may stall or reverse.
The market expects about 11% revenue growth next year and values the stock well below our fair value of $45.43. Our model is more optimistic on recovery and margin improvement than current prices reflect.
Breaks if: Cash from operations falls below zero for two consecutive quarters
Improve cash generated from operating activities and achieve positive free cash flow.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on improving financial performance. The current thesis state is intact, supported by recent earnings beats and a positive shift in company momentum.
The market appears to price TNDM as relatively cheap compared to its peers, with a notable expectations gap. However, the overall valuation reflects a justified status given its loss-making nature and the current economic backdrop.
Management is on track with priorities to increase revenue and pump shipments, showing some progress in cash flow and margin improvements. However, the mixed results in profitability and cash flow suggest that challenges remain.
Key factors include the potential for management to maintain or improve guidance in upcoming calls and the performance of sector bellwethers that could influence TNDM's momentum. Additionally, broader economic conditions, such as job growth, could impact investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the positive outlook. The company's growth plan aims to increase revenue and pump shipments, reinforcing this view. There are no current threats to the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 4 of last 4 quarters. Cash from operating activities improved from negative $18.3 million in 2025-Q1 to positive $11.1 million in 2026-Q2. Management has emphasized improving cash flow and free cash flow, and the financials show delivering progress.
“Cash from operating activities was $11.1 million in 2026-Q2”
“Cash from operating activities was $11.1 million in 2026-Q1”
“Positive cash flow from operating activities of $9.8 million and positive free cash flow of $3.1 million”
“Cash from operating activities was $8.3 million in 2025-Q3”
Breaks if: Gross margin falls below 53% in FY26
Breaks if: Annual revenue falls below $1.0 billion in FY26
Grow international sales by initiating and expanding direct commercial operations in select countries.
Stated in 3 of last 4 quarters. International sales grew from $307.8 million in 2025 to an estimated $335-340 million in 2026, reflecting expansion of direct commercial operations. Management has consistently emphasized international rollout, and the financials show delivering progress.
“Began the international commercial rollout for Tandem Mobi”
“Expanded Tandem Mobi connected care ecosystem internationally”
“Began direct commercial operations in select European countries”
Breaks if: Shipment growth falls below 5% in FY26
Over the next 1 to 3 years, TNDM's performance will depend on its ability to navigate risks while executing its growth and profitability strategies. Not investment advice.